Literature DB >> 30797721

Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System.

Doreen A Ezeife1, Brandon Josh Morganstein2, Sally Lau2, Jennifer H Law2, Lisa W Le3, Jason Bredle4, David Cella5, Mark K Doherty6, Penelope Bradbury2, Geoffrey Liu2, Adrian Sacher2, Frances A Shepherd2, Natasha B Leighl2.   

Abstract

INTRODUCTION: Financial distress has been established as a clinically relevant patient-reported outcome associated with worse mortality and quality of life. Our goal was to define factors associated with financial burden (FB) in a public health care system.
MATERIALS AND METHODS: Patients with advanced lung cancer were recruited from outpatient clinics at the Princess Margaret Cancer Centre (Toronto, Canada). FB was measured with the validated Comprehensive Score for Financial Toxicity (COST) instrument, a 12-item survey scored from 0 to 44, with lower scores reflecting worse financial well-being. Data on patient and treatment characteristics, total out-of-pocket costs (OOP), and private insurance coverage were collected. Multivariable logistic regression models were fit for COST score and each variable, to determine factors associated with greater FB (COST < 21).
RESULTS: Of 251 patients approached, 200 (80%) participated. The median age of the cohort was 65 years; 56% were female. The median total OOP ranged between $1000 and $5000 CAD. The median COST score was 21 (range, 0-44). FB was associated with age, with patients < 65 years reporting greater FB than older patients (COST, 18.0 vs. 24.0; P < .0001). In multivariable logistic regression analysis, younger age was associated with greater FB, when adjusting for income, employment status, OOP, and private insurance coverage (odds ratio, 3.6; 95% confidence interval, 1.5-9.1; P < .0001).
CONCLUSION: Age is significantly associated with FB in the Canadian (Ontario) public health care system, with younger patients with lung cancer reporting greater financial distress. This study highlights priority patient populations where FB should be routinely assessed and appropriate resources for support offered.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cost of cancer care; Financial distress

Mesh:

Year:  2018        PMID: 30797721     DOI: 10.1016/j.cllc.2018.12.010

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  9 in total

1.  Understanding the Financial Needs Following Diagnosis of Breast Cancer in a Setting with Universal Health Coverage.

Authors:  Yek-Ching Kong; Li-Ping Wong; Chiu-Wan Ng; Nur Aishah Taib; Nanthini Thevi Bhoo-Pathy; Mastura Mohd Yusof; Azlina Firzah Aziz; Prathepamalar Yehgambaram; Wan Zamaniah Wan Ishak; Cheng-Har Yip; Nirmala Bhoo-Pathy
Journal:  Oncologist       Date:  2020-01-10

2.  Predictors of financial toxicity and its associations with health-related quality of life and treatment non-adherence in Turkish cancer patients.

Authors:  Duygu Ürek; Özgür Uğurluoğlu
Journal:  Support Care Cancer       Date:  2021-08-15       Impact factor: 3.603

Review 3.  The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review.

Authors:  Nicolas Iragorri; Claire de Oliveira; Natalie Fitzgerald; Beverley Essue
Journal:  Curr Oncol       Date:  2021-03-15       Impact factor: 3.677

4.  Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors.

Authors:  Elizabeth S Ver Hoeve; Leila Ali-Akbarian; Sarah N Price; Nurhyikmah M Lothfi; Heidi A Hamann
Journal:  Support Care Cancer       Date:  2020-05-03       Impact factor: 3.359

5.  Lung Cancer and Self-Management Interventions: A Systematic Review of Randomised Controlled Trials.

Authors:  Rachel Anne Rowntree; Hassan Hosseinzadeh
Journal:  Int J Environ Res Public Health       Date:  2022-01-04       Impact factor: 3.390

6.  The Public Health Insurance Coverage of Novel Targeted Anticancer Medicines in China-In Favor of Whom? A Retrospective Analysis of the Insurance Claim Data.

Authors:  Mingshuang Li; Yifan Diao; Jianchun Ye; Jing Sun; Yu Jiang
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

7.  The Burden of Health-Related Out-of-Pocket Cancer Costs in Canada: A Case-Control Study Using Linked Data.

Authors:  Beverley M Essue; Claire de Oliveira; Tracey Bushnik; Sharon Fung; Jeremiah Hwee; Zhuolu Sun; Elba Gomez Navas; Jean Hai Ein Yong; Rochelle Garner
Journal:  Curr Oncol       Date:  2022-06-27       Impact factor: 3.109

8.  Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol.

Authors:  Silvia Riva; Jane Bryce; Francesco De Lorenzo; Laura Del Campo; Massimo Di Maio; Fabio Efficace; Luciano Frontini; Diana Giannarelli; Lara Gitto; Elisabetta Iannelli; Claudio Jommi; Vincenzo Montesarchio; Francesca Traclò; Concetta Maria Vaccaro; Ciro Gallo; Francesco Perrone
Journal:  BMJ Open       Date:  2019-09-09       Impact factor: 2.692

9.  Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France).

Authors:  Sandra Lassalle; Véronique Hofman; Simon Heeke; Jonathan Benzaquen; Elodie Long; Michel Poudenx; Elisabeth Lantéri; Jacques Boutros; Virginie Tanga; Katia Zahaf; Salomé Lalvée; Virginie Lespinet; Olivier Bordone; Jean-Marc Félix; Christelle Bonnetaud; Charles Marquette; Marius Ilie; Paul Hofman
Journal:  Cancers (Basel)       Date:  2020-04-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.